News & Events
Divided They Conquer – tRNAs Are Segmented Into Fragments In a Manner That Depends on Race, Gender and Tissue, A Finding That May Impact Future Studies Of Disease
In recent years advances in sequencing technology have enabled detailed investigations of the RNA molecules that are active in a cell.
New Family of Small RNAs Boosts Cell Proliferation in Cancer
Rather than cellular trash, half of a transfer RNA (tRNA) molecule appears to actively spur cell proliferation in breast and prostate cancers, suggesting a new role for tRNA and a possible target for a new class of therapy.
Jefferson Professor Lauren Collins, M.D., Selected as Josiah Macy Jr. Foundation 2015 Faculty Scholar
Thomas Jefferson University is proud to announce the selection of Lauren Collins, M.D., as a 2015 Josiah Macy Jr. Foundation Faculty Scholar, one of five selected nationwide.
Stress Hormones Could Undermine Breast Cancer Therapy
Steroids often given to patients to treat the side effects of therapy may cause a subset of breast cancers to become treatment-resistant.
New Sleep Genes Found
Researchers discover that a protein called Taranis could hold the key to a good night’s sleep
Why Obesity Predisposes to Severe Respiratory Failure
A hormone used to regulate insulin levels may be the key to reducing the risk of acute respiratory distress syndrome in obese patients.
Independence Blue Cross & Thomas Jefferson University Announce Innovation Collaboration
To enhance Philadelphia’s role as a global leader in health care innovation, Independence Blue Cross, and Thomas Jefferson University have announced a new partnership to boost innovation.
Population Health Signs Affiliation Agreement with Rutgers-Camden
JCPH and Rutgers University–Camden (RUC) recently signed an affiliation agreement that facilitates priority admission of RUC students to the JSPH Master of Public Health (MPH) degree program.
Jefferson Announces New Faculty Member, Michael E. Mahla, MD
Thomas Jefferson University (Jefferson) welcomed Michael E. Mahla, MD, as Professor of Anesthesiology and Director of Neuroanesthesia at the Sidney Kimmel Medical College
Practice-Changing Study Offers New Option for Tough Breast Cancer Cases
Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.